Indication

As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Medicine details

Medicine name:
blinatumomab (Blincyto)
SMC ID:
SMC2234
Pharmaceutical company
Amgen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q1 2020
SMC meeting date:
Q1 2020
Patient group submission deadline:
04 November 2019